Biotech Values : Thanks for the GLPG CC notes. All I’ll a...

DewDiligence · 2015-09-25T16:27:35.7370000Z

Thanks for the GLPG CC notes. All I’ll add is that ABBV (formerly ABT) has a reputation for playing hardball with small partners. CATG (10 years ago) is a case in point: #msg-8243763.

Play Episode

6min

Proactive - Interviews for investors

SomnoMed lifts revenue 19% amid soaring demand

SomnoMed CO-CEOs Amrita Blickstead and Karen Borg talked with Proactive about the company’s performance and opportunities in the global sleep apnea treatment market. The company, which develops proprietary oral appliances for obstructive sleep apnea, is seeing significant demand as patients seek alternatives to traditional CPAP therapy. “About 60% of people fail to be able to use actual CPAP therapy because it’s quite invasive,” Borg explained. SomnoMed’s devices offer a less intrusive solution and are distributed through dental channels in 28 countries, with strong uptake in the United States and Western Europe. The co-CEOs discussed a major tailwind from the rising use of GLP-1 therapies for weight loss, which is pushing more patients to explore alternative sleep apnea treatments. Increased public awareness of sleep wellness through apps and consumer health trends is also fueling demand. To meet this growth, Blickstead said their immediate focus was on ensuring “the right foundation for profitable growth.” This included strengthening the company’s financial base, reducing costs, paying down debt, and investing heavily in manufacturing. Production capacity has increased by over 40%, with revenue up 19% year-on-year and EBITDA for the first half reaching AUD 5.80 million, compared to a AUD 1.10 million loss previously. Despite these gains, Blickstead noted they are still “chasing our tails and trying to make enough product to continue to grow this business.” #SomnoMed #SleepApnea #OralAppliance #HealthcareInnovation #CPAPAlternative #GLP1 #SleepTech #MedicalDevices #HealthInvesting #ProactiveInvestors

Proactive - Interviews for investors

AI translation tech: Straker CEO talks IBM partnership

Straker Ltd CEO Grant Straker talked with Proactive at AIM"S Small and Midcap Conference about how the company is leveraging artificial intelligence to reshape the global language services industry. Straker explained how the business evolved from early content management systems into a leading AI-powered translation platform over the last 15 years. The company focuses on blending machine learning with human expertise to deliver high-quality, cost-effective language services. A key milestone has been the integration of its platform by IBM, which now uses Straker’s technology for all its internal translations. “They’ve gone from a multi-vendor traditional model to just us,” Straker said, highlighting how the move has streamlined IBM’s operations while reducing costs. He also discussed the company's proprietary "Terry" language model and its innovative quality estimation* system. This tool evaluates translated content for accuracy, determining whether it needs human review—improving efficiency and boosting gross margins. Straker outlined a clear investor case, emphasizing three pillars: financial strength, innovation, and global distribution. The company is targeting revenues of AUD 45 million for the year, with no debt, AUD 12 million in cash, and annual R&D investment of AUD 7 million. With operations in ten countries and strategic alignment with IBM’s AI stack, Straker positioned the company as well-placed to scale quickly through operating leverage in AI. #AI #StrakerLtd #GrantStraker #LanguageTech #TranslationAI #IBMPartnership #ArtificialIntelligence #InvestorUpdate #MachineTranslation #TechStocks #ASXStocks #TerryModel #QualityEstimation #ProactiveInvestors #SmallCapASX

Proactive - Interviews for investors

atai CEO outlines strategic focus for 2025 including four major data readouts

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company's upcoming clinical milestones and strategic focus in 2025. Rao outlined four major clinical readouts across atai’s pipeline of short-duration psychedelics, including updates on VLS-01, BPL-003, RL-007 and EMP-01. The company has dosed its first patient in the VLS-01 trial for treatment-resistant depression, a study that includes an innovative two-dose approach. Rao noted, “This will be the first data set that's going to come out that really addresses the question of what is the incremental benefit of a re-dose?” The trial is expected to read out in Q1 of next year. The BPL-003 trial has completed enrolment and is expected to report results mid-year, alongside RL-007, which targets cognitive impairment associated with schizophrenia. EMP-01, which focuses on social anxiety disorder, is also underway with data expected around the same time as VLS-01. Rao also highlighted that atai recently raised additional capital, extending its funding runway into 2027. The company is focused on short-duration psychedelics with easy-to-administer formulations, such as VLS-01's oral strip delivery system. For more interviews and updates from innovative biotech companies, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future content. #ataiLifeSciences #Biotech #Pharmaceuticals #PsychedelicTherapy #ClinicalTrials #MentalHealth #TreatmentResistantDepression #Schizophrenia #SocialAnxietyDisorder #VLS01 #RL007 #BPL003 #EMP01 #ProactiveInvestors

Proactive - Interviews for investors

Fineqia International CEO unveils first DeFi yield ETP

Fineqia International Inc (CSE:FNQ, OTC:FNQQF) CEO Bundeep Singh Rangar talked with Proactive's Stephen Gunnion about launching the world’s first exchange-traded product (ETP) that deploys digital assets in yield-bearing decentralized finance (DeFi). Rangar explained the product's unique value, providing access to DeFi yield through a transparent, regulated security listed on the Vienna Stock Exchange. The Fineqia FTSE Cardano Enhanced Yield ETN (AV:YADA) is based on the Cardano network, a top ten cryptocurrency valued at over $35 billion, and allows investors to participate in DeFi activities such as borrowing, lending, and validating transactions, which generate fees. Unlike traditional ETFs and ETNs, Fineqia's product reinvests 80% of these yields back to investors, making it a truly innovative approach. Rangar highlighted the importance of partnering with FTSE Russell, a subsidiary of the London Stock Exchange, to ensure robust pricing data for this groundbreaking product. He added, "This is an icebreaker for what we want to do in the industry... We’re about being innovative and different." This collaboration sets a milestone for the ETP industry by combining blockchain technology and traditional finance, giving fund managers and retail investors easy access to decentralized finance through a familiar financial instrument. Visit Proactive's YouTube channel for more videos like this one, and don’t forget to give the video a like, subscribe to the channel, and enable notifications for updates! #Fineqia #DeFi #CryptoETP #DecentralizedFinance #Cardano #DigitalAssets #ETN #CryptoInvesting #Blockchain #FTSERussell

Followers	840
Posts	121365
Boards Moderated	8
Alias Born	09/05/2002

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Join the InvestorsHub Community

Go Ad-Free